RNS Number : 0060S

AstraZeneca PLC

01 November 2019

1 November 2019 15:00 GMT

Transparency Directive

Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 October 2019 the issued share capital of AstraZeneca PLC with voting rights is 1,311,904,600 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,311,904,600.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 Media Relations 
 Gonzalo Viña                                                             +44 203 749 5916 
 Rob Skelding                           Oncology                               +44 203 749 5821 
 Rebecca Einhorn                        Oncology                                +1 301 518 4122 
 Matt Kent                              BioPharmaceuticals                     +44 203 749 5906 
 Jennifer Hursit                        Other                                  +44 203 749 5762 
 Christina Malmberg Hägerstrand    Sweden                                 +46 8 552 53 106 
 Michele Meixell                        US                                      +1 302 885 2677 
 Investor Relations 
 Thomas Kudsk Larsen                                                           +44 203 749 5712 
 Henry Wheeler                          Oncology                               +44 203 749 5797 
 Christer Gruvris                       BioPharmaceuticals (CV, Metabolism)    +44 203 749 5711 
 Nick Stone                             BioPharmaceuticals (Renal), ESG        +44 203 749 5716 
                                        BioPharmaceuticals (Respiratory), 
 Josie Afolabi                           other medicines                       +44 203 749 5631 
 Craig Marks                            Finance, fixed income                  +44 7881 615 764 
 Jennifer Kretzmann                     Corporate access, retail investors     +44 203 749 5824 
 US toll-free                                                                  +1 866 381 72 77 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.



(END) Dow Jones Newswires

November 01, 2019 11:00 ET (15:00 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Astrazeneca Charts.